Daniel Rosenbaum

Daniel Rosenbaum is an experienced executive with a robust background in financial leadership and strategic management across various industries. Currently serving as the Consulting CFO at Burkland since March 2020, Daniel specializes in assisting young companies with financial expertise spanning strategic planning, fundraising, and growth management. Prior roles include CEO of Kaydence Pharma, where Daniel focused on the clinical development of vitamin K2, and CEO and COO of NattoPharma ASA, a leader in Vitamin K2 innovation. Daniel's extensive tenure at FMC Corporation included positions ranging from General Manager to Director, with full P&L responsibility for multiple divisions. Daniel holds an MBA from The Tuck School of Business at Dartmouth and dual degrees from Cornell University in Economics and Sculpture.